about
Emerging trends in hepatocellular carcinoma incidence and mortality.Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical OutcomesResponses of auditory-cortex neurons to structural features of natural sounds.Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent mannerEvaluation of the patient with hepatitis BLong-term therapy of chronic delta hepatitis with peginterferon alfa.Ribavirin improves early responses to peginterferon through improved interferon signalingThe association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver diseaseHCV infection induces a unique hepatic innate immune response associated with robust production of type III interferonsCurrent and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modelingKidney biomarkers associated with blood lead, mercury, and cadmium in premenopausal women: a prospective cohort study.Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.Relating cluster and population responses to natural sounds and tonal stimuli in cat primary auditory cortex.Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection.Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B.Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy.How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.Responses of neurons in cat primary auditory cortex to bird chirps: effects of temporal and spectral context.Hepatic Gi signaling regulates whole-body glucose homeostasis.The relationship between sugar-sweetened beverages and liver enzymes among healthy premenopausal women: a prospective cohort study.Electronic clinical challenges and images in GI. Gastrointestinal malignant melanoma.Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32].Similarity between studies of dihydromyricetin and reservatrol for NAFLD.HSD17B13 is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver DiseaseDevelopment of Hepatic Steatosis After Chemotherapy for Non-Hodgkin LymphomaTransmission of hepatitis B and C viruses--updateRates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysisWhat if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liverLiver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culpritReply to "Does the HSD17B13 rs72613567 splice variant actually yield a new type of alternative splicing"Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study
P50
Q27334932-7B3A7635-A48A-483B-99FC-63C6520300CBQ27488883-83BCC28B-3F88-4B31-AF82-DBA8DBDD9CE4Q30538641-A1BAE85F-EB3E-4F8F-AE3A-AA2576B259D0Q33822643-AC2C0691-7B50-4EC4-B582-31BD45AA1295Q33896660-2C0FDE23-2F1F-4EEE-AD01-700D1DB8981CQ33904679-449D8929-0931-4D69-9C05-9A164B698612Q33987120-7E6A2EA3-5E22-4AEF-A9AB-B8DAE9F88E1FQ34101263-C9354E8D-307E-4AAC-B42B-640F3E087125Q34247460-61FCC829-EE2F-4B48-9357-B035009E8C31Q34540703-6A4247BD-7FB6-44B2-8DE7-CD32CCA6ABDFQ34577514-EAB0BD1A-89AB-4C85-B855-C906E812B36AQ34581526-18BF1EFD-2D10-48B4-8135-F7156EA6FA93Q35748913-0B39DAA9-A69B-4D41-915E-8E270DA3942CQ35964140-BA47A534-F4FC-463D-B63E-45EAEC1EEE50Q35964254-1A9AE316-3DC5-4C7E-BFB6-794B24A58786Q37185209-6C0FEF37-05FA-4C38-BB0E-301733734DA0Q37377964-0EE3A619-ADE8-42E7-AC32-7406C2D483A9Q39027825-07C74A41-C6CF-4058-BCE0-93A12C5797B3Q40722560-2668A97C-133A-497C-B1C6-5DC1C3EFF356Q41711786-CDAAE788-726E-4EE0-A9AD-75309D705D01Q42612437-D038FA5B-1A37-4A31-BFE6-7433BA0055CAQ43037211-312ACB70-517A-43DD-B246-D825002CB739Q45058302-42DF1C70-BCF3-4476-AD8A-75BED5F4B389Q45128319-406F0D61-0529-4F38-B88B-0E90D1128836Q47105153-596D5042-D41E-4A77-8805-BEA932DE7ADEQ48062300-A9620F05-8BC9-4C84-9A12-0AE978208023Q48479670-BDFE2E1C-8B5C-4C25-BA24-2D6279FDDAE1Q50031898-030DB7F2-1999-4837-91A4-B07F76F8C647Q50592816-3B223B1A-B20E-44C4-BEC8-36BB52A0B092Q53410054-A8BB7393-D5DB-4E10-A3D6-B79BA011B814Q53817255-3FF33162-B94A-4307-B10F-804A8E797D22Q53823087-4188BC81-B586-4527-99E4-F5B7FCDE742DQ58554683-FF9EDAE8-A115-46A6-91B5-374E5A7FF92AQ61811926-0AE13C47-8FD0-4312-BC06-C422D2CC9CF0Q74037064-8BC22CA0-B533-4032-A1BB-B65C0E127B34Q89138537-3831FD1F-2CCA-4F2C-95FE-3DB601B7F9B5Q89443853-01CAA26E-A2E2-476E-8BAA-73DEC96A7C8BQ89931628-115B5D04-141C-4E4D-B730-139FEFA7C80EQ91408416-F13D2E4B-331C-4368-A53C-9488213D8601Q91424444-E3173A64-EDE3-43A7-954B-BAA2347685C2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yaron Rotman
@ast
Yaron Rotman
@en
Yaron Rotman
@es
Yaron Rotman
@nl
Yaron Rotman
@sl
type
label
Yaron Rotman
@ast
Yaron Rotman
@en
Yaron Rotman
@es
Yaron Rotman
@nl
Yaron Rotman
@sl
prefLabel
Yaron Rotman
@ast
Yaron Rotman
@en
Yaron Rotman
@es
Yaron Rotman
@nl
Yaron Rotman
@sl
P106
P1153
6506410164
P31
P496
0000-0002-7549-8216